Open
The Marked Chart Wire · Health
Keytruda
Merck reported that its Phase 3 study achieved its main objective. Keytruda alone cut the chance of disease worsening or patient mortality by 43 percent relative to standard chemotherapy for specific advanced cases.
Prices from Live · updated 1:28 PM ET. Each tile opens the stock's chart and news.
New to this? Read: Reading a stock chart
Lung Cancer
Updated findings from a study on first-line non-small cell lung cancer showed lasting benefits when pairing Merck's KEYTRUDA with Eli Lilly's olomorasib.
Cancer Vaccine
The two companies disclosed late-stage clinical findings for their mRNA therapy, intismeran autogene, after an information leak occurred.
Eikon Therapeutics
Eikon Therapeutics stated that EIK1001, used with standard treatments, showed lasting results in advanced non-small cell lung cancer. The company said the side effect profile allows for outpatient care.
Lung Cancer
Hutchmed announced that its Safron Phase III study showed a 45 percent reduction in disease progression or death risk for patients with specific lung cancer mutations when using Orpathys with Tagrisso instead of chemotherapy.
AstraZeneca ADCs
AstraZeneca will seek approval for sonesitatug vedotin after a trial showed a 42 percent reduction in death risk for gastric cancer patients. The company projects peak annual sales of $3 billion to $5 billion for the drug.
BeOne Medicines
BeOne Medicines presented ESMO data for its experimental bispecific antibody. The drug showed a 36 percent confirmed response rate in advanced liver cancer cases with a good safety profile at the Phase 3 dose.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.